Report Overview

The global liver disease treatment market size stood at around USD 10.2 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Malfunctioning of the liver can be life threatening as it can cause multiple acute and chronic diseases (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumour, and liver cirrhosis, among others). The initial symptoms of liver damage include nausea, fatigue, diarrhoea, jaundice, swollen abdomen, and mental disorientation among others. Acute liver damage can be treated through proper medication if detected early, otherwise, a liver transplant is required. Liver damage can be prevented by adopting a healthy lifestyle and practicing proper hygiene



Market Drivers

Key factors such as increasing prevalence of liver diseases, rising geriatric population suffering from liver diseases and various technological advancements in imaging techniques are key drivers for the growth of the market. However, factors such as stringent regulatory framework and high cost of imaging techniques for liver treatment are likely to restrain the market growth to a certain extent

There is increasing geriatric population and technological advancements in imaging techniques which are driving the growth of the market

On the other side, owing the benefits offered by the hybrid imaging systems over the standalone ones, its use is anticipated to one of the prevalent trend considerably over the forecast period

The key restraints of the market are complex drug approval procedure, side-effects of the product (fatigue, fever, and depression), high cost incurred for products R&D process, and competition from alternative medicine (Herbal, Natural medicine)

Major Hepatitis Disease

The major disease includes hepatitis, liver cancer, alcohol induced liver disease and non-alcoholic fatty liver disease. In 2018, cancer held the largest market share. There has been a significant increase in the number of liver cancer cases due to hepatitis infections, smoking, over consumption of alcohol, and obesity. The segment is anticipated to grow with a CAGR of 5.2% during the forecast period